Intravenous Immunoglobulin as a Therapeutic Option in Severe COVID-19 Patient: Case Report
International Journal of Science and Research (IJSR)

International Journal of Science and Research (IJSR)
Call for Papers | Fully Refereed | Open Access | Double Blind Peer Reviewed

ISSN: 2319-7064


Downloads: 57 | Views: 344 | Weekly Hits: ⮙1 | Monthly Hits: ⮙1

Case Studies | Medical Science | Indonesia | Volume 10 Issue 3, March 2021 | Popularity: 6.6 / 10


     

Intravenous Immunoglobulin as a Therapeutic Option in Severe COVID-19 Patient: Case Report

Yulia Karolina Kurniawati, Ongky Aristian, Anak Agung Gde Upeksha


Abstract: Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent for the ongoing pandemic of coronavirus disease 2019 (COVID-19). Until now, no definite effective treatment has been identified. Case Report: This article reports a 41 year old male, diagnosed with Confirmed Pneumonia COVID-19 with hypertension, transaminitis and obesity. The patient received high-dose intravenous immunoglobulin (IVIg) therapy. Conclusion: Patient was treated by intravenous immunoglobulin (IVIg) showed satisfactory recovery. Based on observations, IVIg should be considered in deteriorating patients infected with COVID-19. However further investigations are needed to explain this further.


Keywords: COVID-19, IVIg


Edition: Volume 10 Issue 3, March 2021


Pages: 308 - 311


DOI: https://www.doi.org/10.21275/SR21301132041


Please Disable the Pop-Up Blocker of Web Browser

Verification Code will appear in 2 Seconds ... Wait





Text copied to Clipboard!
Yulia Karolina Kurniawati, Ongky Aristian, Anak Agung Gde Upeksha, "Intravenous Immunoglobulin as a Therapeutic Option in Severe COVID-19 Patient: Case Report", International Journal of Science and Research (IJSR), Volume 10 Issue 3, March 2021, pp. 308-311, https://www.ijsr.net/getabstract.php?paperid=SR21301132041, DOI: https://www.doi.org/10.21275/SR21301132041

Top